Targeting CCDC196 as A Potential Drug for Cancer Treatment (G440184)

Target Name: CCDC196

NCBI ID: G440184

CCDC196

Targeting CCDC196 as A Potential Drug for Cancer Treatment

CCDC196 (NCRNA00238) is a protein that is expressed in various tissues and cells in the body. It is a key regulator of cell-cycle progression and has been implicated in the development and progression of many diseases, including cancer.

One of the most promising aspects of CCDC196 is its potential as a drug target. CCDC196 has been shown to play a role in the regulation of cell division and has been linked to the development of cancer. By targeting CCDC196 with small molecules, researchers may be able to inhibit its activity and potentially treat cancer.

CDC196 is a 22kDa protein that is expressed in a variety of tissues and cells, including muscle, liver, and brain. It is a key regulator of cell-cycle progression and has been implicated in the development and progression of many diseases, including cancer.

One of the most promising aspects of CCDC196 is its potential as a drug target. CCDC196 has been shown to play a role in the regulation of cell division and has been linked to the development of cancer. By targeting CCDC196 with small molecules, researchers may be able to inhibit its activity and potentially treat cancer.

CDC196 has been shown to regulate the G1/S transition, which is a critical step in the cell-cycle progression that leads to cell growth and division. The G1/S transition is also known as the G1 phase and is characterized by increased levels of the protein p21.

In cancer, the G1/S transition is often disrupted, leading to increased cell proliferation and the development of cancer. Targeting CCDC196 with small molecules may be an effective way to inhibit its activity and potentially treat cancer.

Another promising aspect of CCDC196 is its role in the regulation of cell adhesion. CCDC196 has been shown to play a role in the regulation of cell-cell adhesion and has been linked to the development of many diseases, including cancer.

In cancer, the regulation of cell-cell adhesion is often disrupted, leading to the development of cancer cells that are less invasive and more deadly. Targeting CCDC196 with small molecules may be an effective way to inhibit its activity and potentially treat cancer.

In conclusion, CCDC196 is a protein that has been shown to play a critical role in the regulation of cell-cycle progression and has been linked to the development and progression of many diseases, including cancer. Targeting CCDC196 with small molecules may be an effective way to inhibit its activity and potentially treat cancer. Further research is needed to fully understand the role of CCDC196 in the development and progression of cancer and to identify safe and effective small molecules that can be used to target it.

(1) CCDC196 is a 22kDa protein that is expressed in a variety of tissues and cells, including muscle, liver, and brain.

(2) CCDC196 has been implicated in the development and progression of many diseases, including cancer.

(3) The G1/S transition is also known as the G1 phase and is characterized by increased levels of the protein p21.

(4) Targeting CCDC196 with small molecules may be an effective way to inhibit its activity and potentially treat cancer.

(5) The regulation of cell-cell adhesion is often disrupted in cancer, leading to the development of cancer cells that are less invasive and more deadly.

Protein Name: Coiled-coil Domain Containing 196

The "CCDC196 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC196 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets